Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Cost of Revenue (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Cost of Revenue for 4 consecutive years, with $537690.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cost of Revenue rose 381.43% to $537690.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $779090.0, a 88.67% increase, with the full-year FY2024 number at $384765.0, down 18.92% from a year prior.
  • Cost of Revenue was $537690.0 for Q3 2025 at 60 Degrees Pharmaceuticals, up from $50051.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $537690.0 in Q3 2025 to a low of $50051.0 in Q2 2025.
  • A 4-year average of $136572.6 and a median of $92281.0 in 2022 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: crashed 51.32% in 2024, then surged 381.43% in 2025.
  • 60 Degrees Pharmaceuticals' Cost of Revenue stood at $162835.0 in 2022, then dropped by 10.18% to $146257.0 in 2023, then dropped by 19.27% to $118077.0 in 2024, then soared by 355.37% to $537690.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Cost of Revenue are $537690.0 (Q3 2025), $50051.0 (Q2 2025), and $73272.0 (Q1 2025).